Myeloma Minute: The Power of Deep Thinking in Science

Clearing the Decks for Deep Thinking Is Vital in Science

Collaboration has fueled many achievements made by the IMF and the International Myeloma Working Group (IMWG). But scientific advances also come from the kind of “deep thinking” that there is little time for in today’s hectic world. In his blog this week, IMF Chairman Dr. Brian Durie explores why both types of settings are important to push the research needle forward. To read Dr. Durie’s blog, click HERE.

European Medicines Agency Pushes for Empliciti for the Treatment of Multiple Myeloma

The Committee for Medicinal Products for Human Use (CHMP) reviewed the monoclonal antibody Empliciti® (elotuzumab) as part of the European Medicine Agency’s (EMA) accelerated assessment program. After review, CHMP recommended that Empliciti® should be used in combination with lenalidomide and dexamethasone for multiple myeloma patients who have received at least one prior therapy. This EMA recommendation will be sent to the European Commission of the European Union, the body that will make the final decision on authorizing the marketing of Empliciti®’s use. To learn more, click HERE.

Share Your Story for Oral Parity Legislation

Due to an outdated design of insurance benefit form, cancer patients across the country are not able to afford their oral anticancer medications. According to Meghan Buzby, the IMF’s Senior Advocacy Director, “patients on oral therapies are being asked to pay a co-insurance for the cost of the drug. They are often being asked to pay upwards of a $1000 per month, per prescription.” If unequal reimbursement has affected you or someone you know, please write a few sentences that tell a personal story. Share your story HERE, and help pass the Cancer Drug Coverage Parity Act of 2015.

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.